{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:27:22Z","timestamp":1794871642506,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FDM202306017181"],"award-info":[{"award-number":["FDM202306017181"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02900-x","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:32:37Z","timestamp":1774513957000},"page":"970-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0477","authenticated-orcid":false,"given":"Lo\u00efc","family":"Vasseur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Duchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-7391","authenticated-orcid":false,"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-2577","authenticated-orcid":false,"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Genthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-294X","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-0310","authenticated-orcid":false,"given":"Juliette","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lorraine","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5370-9025","authenticated-orcid":false,"given":"Alexandre","family":"Iat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Vaidie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Val\u00e8re","family":"Malfuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Tarfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1973-3444","authenticated-orcid":false,"given":"Pierre","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Penther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Celli-Lebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2900_CR1","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al. Diagnosis and management of AML in adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022; blood.2022016867.","DOI":"10.1182\/blood.2022016867"},{"key":"2900_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, et al. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97:1427\u201334.","journal-title":"Am J Hematol"},{"key":"2900_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4:66\u201375.","journal-title":"Blood Adv"},{"key":"2900_CR4","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213\u201323.","journal-title":"Blood"},{"key":"2900_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood-2014-01-549212","volume":"124","author":"M-A Hospital","year":"2014","unstructured":"Hospital M-A, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, et al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 2014;124:1312\u20139.","journal-title":"Blood"},{"key":"2900_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","volume":"38","author":"C Orvain","year":"2024","unstructured":"Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas P-Y, Iat A, et al. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study. Leukemia. 2024;38:1949\u201357.","journal-title":"Leukemia"},{"key":"2900_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"2900_CR8","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","volume":"28","author":"A Corbacioglu","year":"2010","unstructured":"Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol J Am Soc Clin Oncol. 2010;28:3724\u20139.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2900_CR9","doi-asserted-by":"crossref","unstructured":"Duan W, Liu X, Jia J, Wang J, Gong L, Jiang Q et al. The loss or absence of minimal residual disease of <0\u00b71% at any time after two cycles of consolidation chemotherapy in CBFB\u2013MYH11-positive acute myeloid leukaemia indicates poor prognosis. Br J Haematol. 2021;192:265\u201371.","DOI":"10.1111\/bjh.16745"},{"key":"2900_CR10","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/s41375-018-0086-0","volume":"32","author":"A H\u00f6llein","year":"2018","unstructured":"H\u00f6llein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, et al. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia. 2018;32:2270\u20134.","journal-title":"Leukemia"},{"key":"2900_CR11","doi-asserted-by":"publisher","unstructured":"Prabahran A, Tacey M, Fleming S, Wei A, Tate C, Marlton P et al. Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-\/high-dose cytarabine. Eur J Haematol. 2018. https:\/\/doi.org\/10.1111\/ejh.13089.","DOI":"10.1111\/ejh.13089"},{"key":"2900_CR12","doi-asserted-by":"publisher","unstructured":"Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D et al. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.235721.","DOI":"10.3324\/haematol.2019.235721"},{"key":"2900_CR13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.2019001425","volume":"134","author":"FG R\u00fccker","year":"2019","unstructured":"R\u00fccker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019;134:1608\u201318.","journal-title":"Blood"},{"key":"2900_CR14","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JAL Yin","year":"2012","unstructured":"Yin JAL, O\u2019Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826\u201335.","journal-title":"Blood"},{"key":"2900_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3324\/haematol.2015.131946","volume":"101","author":"C Willekens","year":"2016","unstructured":"Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, et al. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 2016;101:328\u201335.","journal-title":"Haematologica"},{"key":"2900_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2013.186","volume":"27","author":"C Allen","year":"2013","unstructured":"Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27:1891\u2013901.","journal-title":"Leukemia"},{"key":"2900_CR17","doi-asserted-by":"publisher","first-page":"e0146614","DOI":"10.1371\/journal.pone.0146614","volume":"11","author":"W Chen","year":"2016","unstructured":"Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, et al. Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. PloS One. 2016;11:e0146614.","journal-title":"PloS One"},{"key":"2900_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","volume":"133","author":"F Christen","year":"2019","unstructured":"Christen F, Hoyer K, Yoshida K, Hou H-A, Waldhueter N, Heuser M, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133:1140\u201351.","journal-title":"Blood"},{"key":"2900_CR19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00277-021-04432-z","volume":"100","author":"W Duan","year":"2021","unstructured":"Duan W, Liu X, Zhao X, Jia J, Wang J, Gong L, et al. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Ann Hematol. 2021;100:1203\u201312.","journal-title":"Ann Hematol"},{"key":"2900_CR20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","volume":"127","author":"N Duployez","year":"2016","unstructured":"Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451\u20139.","journal-title":"Blood"},{"key":"2900_CR21","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","volume":"4","author":"N Jahn","year":"2020","unstructured":"Jahn N, Terzer T, Str\u00e4ng E, Dolnik A, Cocciardi S, Panina E, et al. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020;4:6342\u201352.","journal-title":"Blood Adv"},{"key":"2900_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3324\/haematol.2021.278645","volume":"107","author":"S Kayser","year":"2022","unstructured":"Kayser S, Kramer M, Mart\u00ednez-Cuadr\u00f3n D, Grenet J, Metzeler KH, Sustkova Z, et al. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022;107:836\u201343.","journal-title":"Haematologica"},{"key":"2900_CR23","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol J Am Soc Clin Oncol. 2005;23:5705\u201317.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2900_CR24","doi-asserted-by":"crossref","unstructured":"Opatz S, Bamopoulos SA, Metzeler KH, Herold T, Ksienzyk B, Br\u00e4undl K et al. The clinical mutatome of core binding factor leukemia. Leukemia. 2020;34:1553\u201362.","DOI":"10.1038\/s41375-019-0697-0"},{"key":"2900_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","volume":"121","author":"P Paschka","year":"2013","unstructured":"Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121:170\u20137.","journal-title":"Blood"},{"key":"2900_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00277-024-06182-0","volume":"104","author":"S Yu","year":"2025","unstructured":"Yu S, Yang S, Hu L, Duan W, Zhao T, Qin Y, et al. Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia. Ann Hematol. 2025;104:997\u20131006.","journal-title":"Ann Hematol"},{"key":"2900_CR27","doi-asserted-by":"crossref","unstructured":"Yang M, Wang W, Zhang G, Qiu S, Liu B, Mi Y et al. Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia. Haematologica. 2025;110:2281\u201392.","DOI":"10.3324\/haematol.2024.287293"},{"key":"2900_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hon.3015","volume":"40","author":"J Wang","year":"2022","unstructured":"Wang J, Dao F-T, Wang Y, Jiang H, Xu L-P, Zhao X-S, et al. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematol Oncol. 2022;40:724\u201333.","journal-title":"Hematol Oncol"},{"key":"2900_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2900_CR30","first-page":"141","volume":"5","author":"OO Aalen","year":"1978","unstructured":"Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141\u201350.","journal-title":"Scand J Stat"},{"key":"2900_CR31","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1002\/sim.5783","volume":"32","author":"Q Chen","year":"2013","unstructured":"Chen Q, Wang S. Variable selection for multiply-imputed data with application to dioxin exposure study. Stat Med. 2013;32:3646\u201359.","journal-title":"Stat Med"},{"key":"2900_CR32","doi-asserted-by":"crossref","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J et al. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood. 2024; blood.2024024310.","DOI":"10.1182\/blood.2024024310"},{"key":"2900_CR33","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1182\/bloodadvances.2023011771","volume":"8","author":"RE van Weelderen","year":"2024","unstructured":"van Weelderen RE, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, et al. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. Blood Adv. 2024;8:3200\u201313.","journal-title":"Blood Adv"},{"key":"2900_CR34","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","volume":"25","author":"K Tarlock","year":"2019","unstructured":"Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries R, Loken MR, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:5038\u201348.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"2900_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","volume":"106","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schw\u00e4ble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106:265\u201373.","journal-title":"Blood"},{"key":"2900_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/leu.2015.141","volume":"30","author":"R Sood","year":"2016","unstructured":"Sood R, Hansen NF, Donovan FX, Carrington B, Bucci D, Maskeri B, et al. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2016;30:501\u20134.","journal-title":"Leukemia"},{"key":"2900_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/ng.3709","volume":"48","author":"ZJ Faber","year":"2016","unstructured":"Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551\u20136.","journal-title":"Nat Genet"},{"key":"2900_CR38","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.leukres.2012.07.001","volume":"36","author":"E Cornet","year":"2012","unstructured":"Cornet E, Dum\u00e9zy F, Roumier C, Lepelley P, Jouy N, Philippe N, et al. Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leuk Res. 2012;36:1330\u20133.","journal-title":"Leuk Res"},{"key":"2900_CR39","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1182\/blood-2024-199996","volume":"144","author":"A Soboli","year":"2024","unstructured":"Soboli A, Tierens AM, Escano L, Jerkfelt M, Rehammar A, Osnes LTN, et al. Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1. Blood. 2024;144:2954.","journal-title":"Blood"},{"key":"2900_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood.2024024264","volume":"144","author":"JA Cook","year":"2024","unstructured":"Cook JA, Lott L, Perry J, Eckel AM, Xu D, Hudson CA, et al. Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML. Blood. 2024;144:581\u20135.","journal-title":"Blood"},{"key":"2900_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/leu.2008.220","volume":"23","author":"H Tamaki","year":"2009","unstructured":"Tamaki H, Yoshihara S, Fujioka T, Kawakami M, Oka Y, Ogawa H. Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia. Leukemia. 2009;23:424\u20136.","journal-title":"Leukemia"},{"key":"2900_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/jclinpath-2017-204828","volume":"71","author":"A Keegan","year":"2018","unstructured":"Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, et al. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018;71:653\u20138.","journal-title":"J Clin Pathol"},{"key":"2900_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2012-07-442772","volume":"121","author":"S Schwind","year":"2013","unstructured":"Schwind S, Edwards CG, Nicolet D, Mr\u00f3zek K, Maharry K, Wu Y-Z, et al. inv(16)\/t(16;16) acute myeloid leukemia with non\u2013type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013;121:385\u201391.","journal-title":"Blood"},{"key":"2900_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/bloodadvances.2024014672","volume":"9","author":"R Joudinaud","year":"2025","unstructured":"Joudinaud R, Boudry A, Fenwarth L, Geffroy S, Salson M, Dombret H, et al. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia. Blood Adv. 2025;9:365\u201374.","journal-title":"Blood Adv"},{"key":"2900_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bioinformatics\/btq035","volume":"26","author":"D Dunkler","year":"2010","unstructured":"Dunkler D, Schemper M, Heinze G. Gene selection in microarray survival studies under possibly non-proportional hazards. Bioinforma Oxf Engl. 2010;26:784\u201390.","journal-title":"Bioinforma Oxf Engl"},{"key":"2900_CR46","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajh.27547","volume":"100","author":"R Cairoli","year":"2025","unstructured":"Cairoli R, Gatti A, Grillo G, Stefanucci MR, Di Camillo B, Fumagalli M, et al. Efficacy of midostaurin combined with intensive chemotherapy in core binding factor leukemia: a phase II clinical trial. Am J Hematol. 2025;100:346\u20139.","journal-title":"Am J Hematol"},{"key":"2900_CR47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2023;401:1571\u201383.","journal-title":"Lancet Lond Engl"},{"key":"2900_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"2900_CR49","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol J Am Soc Clin Oncol. 2024;42:1158\u201368.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2900_CR50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"2900_CR51","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41375-025-02700-9","volume":"39","author":"J Ronnacker","year":"2025","unstructured":"Ronnacker J, Muller PJ, Mikesch J-H, Zukunft S, Weinbergerov\u00e1 B, \u0160r\u00e1mek J, et al. Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis. Leukemia. 2025;39:2174\u201380.","journal-title":"Leukemia"},{"key":"2900_CR52","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1007\/s00432-022-04356-9","volume":"149","author":"M Hanoun","year":"2023","unstructured":"Hanoun M, Ruhnke L, Kramer M, Hanoun C, Sch\u00e4fer-Eckart K, Steffen B, et al. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. J Cancer Res Clin Oncol. 2023;149:4611\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2900_CR53","doi-asserted-by":"publisher","first-page":"EVIDoa2400326","DOI":"10.1056\/EVIDoa2400326","volume":"4","author":"M Hunault","year":"2025","unstructured":"Hunault M, Pautas C, Bertoli S, Dumas P-Y, Raffoux E, Hospital M-A, et al. Intermediate-dose cytarabine as postinduction AML therapy. NEJM Evid. 2025;4:EVIDoa2400326.","journal-title":"NEJM Evid"},{"key":"2900_CR54","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1002\/ajh.26057","volume":"96","author":"S Arslan","year":"2021","unstructured":"Arslan S, Zhang J, Dhakal P, Moran J, Naidoo N, Lombardi J, et al. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. Am J Hematol. 2021;96:E59\u2013E63.","journal-title":"Am J Hematol"},{"key":"2900_CR55","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3324\/haematol.2014.114884","volume":"100","author":"N Boissel","year":"2015","unstructured":"Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica. 2015;100:780\u20135.","journal-title":"Haematologica"},{"key":"2900_CR56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","volume":"4","author":"G Marcucci","year":"2020","unstructured":"Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020;4:696\u2013705.","journal-title":"Blood Adv"},{"key":"2900_CR57","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1182\/blood.2021014520","volume":"139","author":"HM Murdock","year":"2022","unstructured":"Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley B, Manning BS, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022;139:3546\u201357.","journal-title":"Blood"},{"key":"2900_CR58","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","volume":"32","author":"P Paschka","year":"2018","unstructured":"Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018;32:1621\u201330.","journal-title":"Leukemia"},{"key":"2900_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00928-1","volume":"13","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang X, Xu Y, Xue S, Qiu H, Tang X, et al. Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood Cancer J. 2023;13:155.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02900-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:13:27Z","timestamp":1778109207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02900-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02900-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}